www.grunenthal.com
Open in
urlscan Pro
2620:1ec:29:1::45
Public Scan
Submitted URL: https://changepain.com/
Effective URL: https://www.grunenthal.com/
Submission: On September 22 via api from US — Scanned from NL
Effective URL: https://www.grunenthal.com/
Submission: On September 22 via api from US — Scanned from NL
Form analysis 1 forms found in the DOM
<form>
<i class="icon-magnify-glass"></i>
<div class="component search-box search-header initialized"
data-properties="{"endpoint":"/en/sxa/search/results/","suggestionEndpoint":"/en/sxa/search/suggestions/","suggestionsMode":"ShowSearchResults","resultPage":"/en/searchresults","targetSignature":"","v":"{4C46236D-8ECA-4A39-9FB9-A8E47DE0EA6D}","s":"{6E567687-8BD2-4C66-9808-C7977B9F904F}","p":5,"l":"","languageSource":"AllLanguages","searchResultsSignature":"","itemid":"{AE6EFEDE-88E3-45CE-B584-AE1C424C26AA}","minSuggestionsTriggerCharacterCount":2}">
<div class="component-content">
<label for="textBoxSearch"> Search results </label>
<span class="twitter-typeahead" style="position: relative; display: inline-block;"><input type="text" class="search-box-input tt-hint" autocomplete="off" maxlength="100" readonly="" spellcheck="false" tabindex="-1" dir="ltr"
style="position: absolute; top: 0px; left: 0px; border-color: transparent; box-shadow: none; opacity: 1; background: none 0% 0% / auto repeat scroll padding-box border-box rgb(255, 255, 255);"><input type="text"
class="search-box-input tt-input" autocomplete="off" name="textBoxSearch" maxlength="100" placeholder="Search here..." spellcheck="false" dir="auto" aria-activedescendant="" aria-owns="undefined_listbox" role="combobox" aria-readonly="true"
aria-autocomplete="list" style="position: relative; vertical-align: top; background-color: transparent;"><span role="status" aria-live="polite"
style="position: absolute; padding: 0px; border: 0px; height: 1px; width: 1px; margin-bottom: -1px; margin-right: -1px; overflow: hidden; clip: rect(0px, 0px, 0px, 0px); white-space: nowrap;"></span>
<pre aria-hidden="true"
style="position: absolute; visibility: hidden; white-space: pre; font-family: visuelt-regular, Arial, sans-serif; font-size: 22px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
<div role="listbox" class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
<div role="presentation" class="tt-dataset tt-dataset-0"></div>
</div>
</span>
<button class="search-box-button-with-redirect" type="submit"> Search </button>
</div>
</div>
</form>Text Content
Consent to Cookies & Data processing
Grünenthal is using technologies like cookies and we process personal data
(IP-address, cookie ID, browser information, viewed content) in order to
optimize and personalize the content and advertising that you see on this
webpage. This helps us to show you more relevant ads and improves your internet
experience. We also use it in order to measure results or align our website
content. For this purpose, we store and access information like cookie IDs on
your device and also create user profiles based on your behavior on our
websites. We also share this data with our partners as announced in the cookie
settings and in our Privacy Statement.
Because we value your privacy, we are herewith asking for your permission to use
these technologies. If you click “Accept all” or accept specific tools, you also
consent that your personal data will be transferred to countries outside of the
EU, in particular to the US, where there might be a lower level of data
protection. You can always change/withdraw your consent with future effect later
by clicking on the settings button on the left lower corner of the page.
Accept all Reject allSave + Exit
Customize your choice | Cookies | Our privacy policy | T&C | Imprint
powered by consentmanager.net
* Contact
* Press Room
* Search
*
*
* Country
* Austria
* Brazil
* Chile
* Colombia
* Ecuador
* France
* Germany
* Great Britain
* Ireland
* Italy
* Mexico
* Netherlands
* Peru
* Portugal
* Spain
* Switzerland
*
*
*
* A World Free of Pain
* Understanding Pain
* Pain Insights
* Pain Basics
* Key Pain Conditions
* Pain Management
* Initiatives & Grants
* Change Pain
* EFIC-Grünenthal-Grant
* Patient Collaborations
* Company
* We are Grünenthal
* History
* Leadership
* Supervisory Board
* Partnering
* Areas of interest
* Public Private Partnerships
* Contract Manufacturing Business
* Global presence & sites
* Affiliates in Asia
* Affiliates in Europe
* Affiliates in the USA & Latin America
* Manufacturing Sites
* Products
* Responsibility
* Our Corporate Responsibility Programme
* One strategic approach
* Four fields of action to ensure maximum positive impact
* Twelve key topics with clear targets
* Compliance, Ethics and Transparency
* Patient – How we support patients in need
* Responsible Use of Pain Medication
* Awareness & Accessibility
* Responsible Innovation
* Product Governance & Safety
* People – How we work with employees, partners and communities
* Human Capital Fairness
* Equality, Diversity and Inclusion
* Attractive Employer
* Employee Engagement
* Planet – What we do for a sustainable future
* Environmental Excellence Strategy
* Responsible Use of Resources
* Our Impact on Climate
* Responsible Sourcing
* Thalidomide
* Science
* R&D approach
* Innovation Hubs
* Collaboration
* Pipeline
* RTX (Resiniferatoxin)
* Therapeutic areas
* Peripheral neuropathic pain
* Chronic post-surgical pain
* Chronic low back pain
* Osteoarthritis
* Clinical trials
* Clinical trial portal
* Clinical data sharing
* Careers
* Creditors
* Media
* Our Stories
* Press releases
* 2024
* 2023
* 2022
* 2021
* 2020
* 2019
* Statements
* Corporate publications
* Image resources
* Video resources
* Understanding Pain
* Pain Insights
* Pain Management
* Initiatives & Grants
* Patient Collaborations
Grünenthal is a global leader in pain management. Our purpose is to change lives
for the better – and our vision is a world free of pain. Innovation is our
passion. We are driven to seek effective, life-changing medicines and solutions
for patients with severe diseases and high unmet medical needs.
... A World Free of Pain
... Understanding Pain
* Pain Basics
* Key Pain Conditions
Learn about the essentials behind pain and gain in-depth knowledge on key pain
conditions with high unmet needs.
... Pain Insights
... Pain Management
* Change Pain
* EFIC-Grünenthal-Grant
We are dedicated to creating a better future for our patients, so getting
involved with diverse initiatives that support this goal is vital.
... Initiatives & Grants
Grünenthal is committed to embedding patient engagement through each stage in
the lifecycle of our medicines and beyond.
... Patient Collaborations
* We are Grünenthal
* History
* Leadership
* Supervisory Board
* Partnering
* Global presence & sites
* Products
Grünenthal is a global leader in pain management. Our purpose is to change lives
for the better – and innovation is our passion. We are driven to seek effective,
life-changing medicines and solutions for patients with severe diseases and high
unmet medical needs.
... Company
A world free of pain. This is our shared vision. To bring it to life, we execute
our strategy and work on our company’s culture – everyday, everywhere, every one
of us.
... We are Grünenthal
Although firmly rooted in Germany, today we are very much a growing global
Business.
... History
A mix of strong entrepreneurial spirit, close collaboration and outstanding
performance define our approach to leadership alongside a commitment to
diversity and inclusivity.
... Leadership
The Supervisory Board advises and controls the Corporate Executive Board and is
elected by the shareholders’ summit.
... Supervisory Board
* Areas of interest
* Public Private Partnerships
* Contract Manufacturing Business
Grünenthal is a global leader in pain management. Our purpose is to change lives
for the better – and innovation is our passion. We are driven to seek effective,
life-changing medicines and solutions for patients with severe diseases and high
unmet medical needs.
... Partnering
* Affiliates in Asia
* Affiliates in Europe
* Affiliates in the USA & Latin America
* Manufacturing Sites
In view of our vision of a World Free of Pain, Grünenthal strives to provide
effective medication to patients worldwide. Therefore, we continuously grow and
expand our market presence and product portfolio, and we collaborate with
commercial partners and multiple stakeholders from the pain management field and
beyond.
... Global presence & sites
Grünenthal’s product portfolio, brands, ingredients and indication range.
... Products
* Our Corporate Responsibility Programme
* Compliance, Ethics and Transparency
* Patient – How we support patients in need
* People – How we work with employees, partners and communities
* Planet – What we do for a sustainable future
* Responsible Sourcing
* Thalidomide
As a global leader in pain management, conducting business responsibly is a core
part of our company’s strategy and culture. We provide transparent
responsibility and sustainability reporting on our progress, and an independent
agency regularly rates our performance according to environmental, social and
governance (ESG) criteria. We join forces for sustainability and are committed
to supporting the United Nations Sustainable Development Goals (SDGs).
... Responsibility
* One strategic approach
* Four fields of action to ensure maximum positive impact
* Twelve key topics with clear targets
Corporate responsibility is at the core of our business strategy and culture. It
runs through everything we do. We want to create a net positive impact for
patients, employees, partners and wider society, and work towards reducing our
impact on the environment.
... Our Corporate Responsibility Programme
We believe compliance, ethics and transparency go hand in hand. Excellence in
this area is a key topic for us – and is deeply anchored in our culture.
... Compliance, Ethics and Transparency
* Responsible Use of Pain Medication
* Awareness & Accessibility
* Responsible Innovation
* Product Governance & Safety
Having access to appropriate pain treatment is a basic human right. As a leader
in pain management, we help to educate healthcare professionals and patients on
how to use these medicines responsibly. We also raise awareness and increase
accessibility to current treatments while developing new medicines for unmet
medical needs.
... Patient – How we support patients in need
* Human Capital Fairness
* Equality, Diversity and Inclusion
* Attractive Employer
* Employee Engagement
How can we have a positive impact on the lives of the people we work with, our
partners and wider society? Find out what we do to foster trust and promote
diversity and inclusion, how we empower our employees to be their best and look
after their health and wellbeing, and how we contribute to improving the quality
of life for people and communities around us.
... People – How we work with employees, partners and communities
* Environmental Excellence Strategy
* Responsible Use of Resources
* Our Impact on Climate
We join together with our employees, partners and customers to reduce our carbon
footprint, save energy and resources, and decrease waste in our value chain.
... Planet – What we do for a sustainable future
The Grünenthal Responsible Sourcing Programme will increase transparency and
help create a positive ESG impact in our supply chain and connected local
communities.
... Responsible Sourcing
... Thalidomide
* R&D approach
* Collaboration
* Pipeline
* Therapeutic areas
* Clinical trials
Our company has a clear vision of a world free of pain and we maintain a
laser-sharp focus on this vision in everything we do – especially in our
research and development activities.
... Science
* Innovation Hubs
We follow a holistic and solution-agnostic approach to deliver highly effective
pain treatments, building our programmes on a firm foundation of human
pathophysiology and solid human target validation.
... R&D approach
... Collaboration
* RTX (Resiniferatoxin)
To move closer to our vision of a world free of pain, we are currently pursuing
a range of programmes across different modalities, targets and mechanisms of
action.
... Pipeline
* Peripheral neuropathic pain
* Chronic post-surgical pain
* Chronic low back pain
* Osteoarthritis
Grünenthal is pursuing four key pain indications: peripheral neuropathic pain,
chronic postoperative pain, chronic low back pain, and osteoarthritis.
... Therapeutic areas
* Clinical trial portal
* Clinical data sharing
As a research-based pharmaceutical company, Grünenthal recognizes the importance
of publicly registering clinical trials and making information including results
available.
... Clinical trials
* Our Stories
* Press releases
* Statements
* Corporate publications
* Image resources
* Video resources
Explore our media section and access a range of materials relating to our
company, people, medicines and medical devices.
... Media
Grünenthal is a global leader in pain management and related diseases. Our
purpose is to change lives for the better – and innovation is our passion. We
are focusing all of our activities and efforts on moving towards our vision of a
world free of pain. Explore our recent stories to see what drives us.
... Our Stories
* 2024
* 2023
* 2022
* 2021
* 2020
* 2019
In this section you will find both current and archived press releases published
from 2013 onwards by Grünenthal GmbH, Germany.
... Press releases
... Statements
Journalists are invited to use our corporate publications for their reporting.
The list contains business related publication like the company presentation or
the code of conduct. .
... Corporate publications
Journalists are invited to use images from our library to illustrate their
reporting. The library contains company and R&D related pictures.
... Image resources
The library contains a set of company footage. Journalists are invited to use
the video material to illustrate their reporting.
... Video resources
Search results
Search
A WORLD FREE OF PAIN
Out now: Virtual company showcase
GRÜNENTHAL IS A GLOBAL LEADER IN PAIN MANAGEMENT.
Grünenthal is a global leader in pain management and related diseases. As a
science-based, privately-owned pharmaceutical company, we have a long track
record of bringing innovative treatments and state-of-the-art technologies to
patients worldwide. Our purpose is to change lives for the better, and
innovation is our passion. We are focusing all our activities and efforts on
working towards our vision of a world free of pain.
GRÜNENTHAL STORIES
View All
100% renewable electricity
Energy contributes more than three-quarters of greenhouse gas emissions
worldwide. That is why people and businesses are switching to green energy. And
Grünenthal’s manufacturing sites now use 100 percent renewable electricity.
12 September 2024
Building trust with investors
Trust is the most important currency for investors. But how do people at
Grünenthal earn and build that trust? Two representatives from our Investor
Relations team share insights into their daily work of creating long-term,
successful relationships with the financial community.
10 September 2024
Headquarters powered by sunshine
The largest solar power facility in the city of Aachen is now up and running at
Grünenthal’s headquarters in Germany. It is the latest milestone in our
commitment to reducing CO2 emissions and contributing to a more sustainable
future. Read more…
29 August 2024
Inclusion in Chile
Grünenthal strives to create a culture of inclusion where all employees can
unleash their full potential. Our Chilean colleague, Rodrigo Caceres, shares his
inspiring story of how inclusion works at our company in this short interview…
26 August 2024
IASP 2024 – 50 years of pain research
The 2024 world congress on pain, held in Amsterdam, brought together more than
5,000 visitors from over 130 countries – and our team was in the thick of it.
20 August 2024
Grünenthal achieves Gold Medal in EcoVadis assessment
We are delighted to announce that Grünenthal has won a Gold Medal in the latest
EcoVadis assessment.
25 July 2024
ANNUAL REPORT 2023/24
4,400 Grünenthal employees worldwide join forces every day to drive progress
towards our vision of a World Free of Pain. Together, we achieved record
revenues in 2023. And our scientists made important progress with developing
innovative medicines for pain patients.
Our most recent report shares information about our company’s strategy,
highlight projects and financial performance.
... Check out the Grünenthal Report.
GRÜNENTHAL 2023 FULL-YEAR RESULTS
In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10
percent over prior year. The adjusted EBITDA was €427 million, a decrease of
three percent vs. prior year due to increased investments in growth through
Research & Development (R&D), acquisitions, and modernising production
facilities. Grünenthal has more than tripled its adjusted EBITDA since 2017.
Grünenthal’s R&D pipeline has progressed substantially with its Phase III
development projects of RTX and Qutenza™.
... Read the 2023 full-year results press release
RESPONSIBILITY REPORT 2023
Grünenthal’s strategy and culture are closely tied to its deep commitment to
conducting business responsibly. We aim to have a net-positive impact on
patients, employees, partners, and wider society. Each year, we publish our
progress in a detailed and externally audited report – in line with the Global
Reporting Initiative (GRI) standards.
... Check out our latest Responsibility Report.
We need your approval
This content is provided by Vimeo. By enabling this content, your personal data
may be processed by the vendor and cookies may be set.
Accept
Always accept Vimeo
powered by consentmanager.net
Our commitment to the PSCI
Grünenthal is a member of the Pharmaceutical Supply Chain Initiative (PSCI)
(https://pscinitiative.org/home). This global movement is driving positive
change in our industry through collaboration to promote more responsible and
sustainable practices along the entire value chain. It brings together pharma
companies, suppliers and other stakeholders with the shared mission of promoting
progress. By working together, we aim to ensure access to safe and reliable
medicines for patients worldwide.
... Find more information about Grünenthal’s commitment to responsible sourcing
here.
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy
designation to resiniferatoxin for pain associated with knee osteoarthritis
(OA). The investigational, non-opioid medicine is currently in Phase III
clinical development.
Knee OA affects more than 360 million people worldwide. Patients often
experience severe pain, and many are impacted in their daily activities. If
approved, resiniferatoxin could become a meaningful treatment option providing
long-lasting pain relief and functional improvement of the affected joint.
Learn more about our asset and how it may address one of the most common and
severe symptoms in knee OA
... Download PR FDA Breakthrough Therapy Designation for Grünenthal’s
resiniferatoxin
We need your approval
This content is provided by Vimeo. By enabling this content, your personal data
may be processed by the vendor and cookies may be set.
Accept
Always accept Vimeo
powered by consentmanager.net
CAREERS
Working at Grünenthal means experiencing the impact you can have on the results
we achieve and the lives of the patients we serve.
Join forces.
Make an impact.
Innovate for a world free of pain.
... Visit our careers website
This website is for all those with an interest in the global business of
Grünenthal
SITES & CHANNELS
* Careers
* LinkedIn
* Instagram
SERVICES
* Contact form
* Reporting side effects
* Medical information request
* Job offers
MEMBERSHIPS
* EFPIA
* IFPMA
* PSCI
Youtube Facebook
Grünenthal 2024 ©
General Terms and Conditions Terms of Use Website Privacy Statement Other
Privacy Statements Imprint Sitemap
Privacy settings
External Link:
You are now leaving the Grünenthal website. You will be re-directed to an
external website. Grünenthal accepts no responsibility for the content of other
websites. ... Cancel ... Ok